Latest TVTX news and sentiment

Travere receives patent allowance for FILSPARI use in FSGS

Travere Therapeutics Inc. announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for a patent covering certain methods of using its drug FILSPARI (sparsentan) in focal segmental glomerulosclerosis (FSGS). This patent is expected to provide U.S. coverage for FILSPARI in FSGS until October 2037. The company plans to list the patent in the FDA's Orange Book, further securing its intellectual property for the rare disease treatment.

Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in Focal Segmental Glomerulosclerosis

Travere Therapeutics announced that the U.S. Patent and Trademark Office issued a Notice of Allowance for a patent application covering methods of using FILSPARI® (sparsentan) in focal segmental glomerulosclerosis (FSGS). This patent is expected to provide U.S. coverage until October 2037 and will be listed in the FDA's "Orange Book." The company also recently received a separate U.S. patent for sparsentan's use in IgA nephropathy.

Travere Therapeutics (TVTX) Sets CEO Handover For December 2026

Why Everyone Is Watching Travere Therapeutics (TVTX) Today

Travere Therapeutics (TVTX) is experiencing investor focus due to an upcoming leadership change, with CEO Eric Dube stepping down on December 1, 2026. The stock currently trades at a significant discount to analyst targets and fair value estimates, driven by the potential expansion of its drug Filspari's label to treat FSGS. While the company shows strong long-term shareholder returns, its future relies heavily on the success of Filspari, posing both opportunity and execution risks.

Travere Therapeutics Announces Planned Chief Executive Officer Transition

Travere Therapeutics announced that its President and CEO, Eric Dube, Ph.D., will step down in December 2026 due to personal health and family reasons after eight years of leadership. Bradley L. Campbell, former president and CEO of Amicus Therapeutics, will succeed him, effective December 1, 2026. Dube will remain as an executive advisor until February 2027 to ensure a smooth transition, as Campbell aims to build on Travere's momentum in rare disease therapies.

Travere Therapeutics President and CEO Eric Dube Plans to Step Down

Travere Therapeutics (TVTX) announced that its President and CEO, Eric Dube, plans to step down. The information was released late Monday by MT Newswires. Further details regarding Dube's departure are available to premium subscribers.

Travere Therapeutics (NASDAQ:TVTX) Passes Minervini Trend Template With High-Growth Momentum

Travere Therapeutics EVP Peter Heerma sells $17.8m in company stock

Peter Heerma, EVP and CCO at Travere Therapeutics (NASDAQ:TVTX), sold approximately $17.86 million worth of company stock through a pre-arranged trading plan between September 15-17, 2026. Concurrently, he acquired about $4.05 million in common stock by exercising employee options. These transactions occurred as TVTX shares approached a 52-week high, with the stock deemed overvalued by InvestingPro analysis, despite the company reporting strong Q2 2026 revenue driven by its kidney drug, FILSPARI.

Travere Therapeutics to Present at the Stifel 2026 Virtual Immunology and Inflammation Forum

Travere Therapeutics, Inc. (Nasdaq: TVTX) announced that its management will present at the Stifel 2026 Virtual Immunology and Inflammation Forum on Thursday, September 24, 2026, at 10:30 a.m. ET. A live webcast of the presentation will be available on the Investor page of Travere’s website, with a replay accessible for up to 30 days. The company, a biopharmaceutical firm focused on rare diseases, aims to develop and deliver life-changing therapies to patients and caregivers.

TVTX Stock Slides 6% On Everest Deal, Erases Some Losses As Analyst Sees 49% Upside

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Travere Therapeutics announced that its Board of Directors' Compensation Committee granted inducement equity awards to 16 new employees. These grants, totaling 56,220 restricted stock units (RSUs), are an inducement for their employment under Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over four years, with 25% vesting annually, contingent on continued employment.

Travere Therapeutics stock hits 52-week high at 68.25 USD

Travere Therapeutics (TVTX) stock reached a new 52-week high of $68.25, marking a significant 172.32% increase over the past year due to strong investor confidence and 77% revenue growth. The company's kidney drug, FILSPARI, has been a key driver, with second-quarter revenue exceeding forecasts at $169.6 million. Despite appearing overvalued, analysts predict profitability for TVTX this year.

FDA issues Untitled Letter to Travere Therapeutics over visual aid for kidney disease drug Filspari

The FDA's Office of Prescription Drug Promotion has issued an Untitled Letter to Travere Therapeutics concerning its visual aid for the kidney disease drug, Filspari. The agency claims that several statements in the visual aid, intended for physicians, are misleading as they are not supported by clinical data. The FDA highlighted issues with claims regarding "kidney preservation," "complete remission of proteinuria," and the drug being "well tolerated," demanding a response from Travere Therapeutics within 15 working days.

Travere Therapeutics' Outlook Brightens As Turnaround Looms

Biotech name Travere Therapeutics is not profitable yet but a turnaround may be around the corner as the stock hovers near a buy zone. Continue Reading

TVTX Stock Slides 6% On Everest Deal, Erases Some Losses As Analyst Sees 49% Upside

Travere Therapeutics CFO Christopher R. Cline Executes 642-Share Sale for Tax Withholding on RSU Vesting

Christopher R. Cline, CFO of Travere Therapeutics, sold 642 shares of common stock on September 2, 2026, at $66.37 per share. This transaction was not a discretionary trade but a mandatory "sell to cover" to fulfill tax withholding obligations arising from vested restricted stock units. Following the sale, Cline beneficially owns 118,016 shares of the company's common stock.